Article
Breakingviews - Investors reject Sanofi's cure to sickly valuation
Rating:
0.0
Views:
64
Likes:
1
Library:
1
Sanofi investors dislike CEO Paul Hudson's prescription to reinvigorate the pharmaceutical group's weak valuation. Shares in the $130 billion French drug giant dropped 15% on Friday after it said it would ramp up research and development spending to build a better pipeline of future drugs. That will cause 2024 earnings to fall at a low single-digit rate compared to 2023 levels before a “strong rebound” in 2025, the company said.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value